EA200000487A1 - Композиция пролонгированного высвобождения - Google Patents

Композиция пролонгированного высвобождения

Info

Publication number
EA200000487A1
EA200000487A1 EA200000487A EA200000487A EA200000487A1 EA 200000487 A1 EA200000487 A1 EA 200000487A1 EA 200000487 A EA200000487 A EA 200000487A EA 200000487 A EA200000487 A EA 200000487A EA 200000487 A1 EA200000487 A1 EA 200000487A1
Authority
EA
Eurasian Patent Office
Prior art keywords
provides
sustained release
composition
present
venlafaxine hydrochloride
Prior art date
Application number
EA200000487A
Other languages
English (en)
Inventor
Дебора Мари Шерман
Джон Клифтон Кларк
Джон Ульрик Лэмер
Original Assignee
Американ Хоум Продактс Корпорейшн
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=25508423&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=EA200000487(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Американ Хоум Продактс Корпорейшн filed Critical Американ Хоум Продактс Корпорейшн
Publication of EA200000487A1 publication Critical patent/EA200000487A1/ru

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5005—Wall or coating material
    • A61K9/5021—Organic macromolecular compounds
    • A61K9/5036—Polysaccharides, e.g. gums, alginate; Cyclodextrin
    • A61K9/5042—Cellulose; Cellulose derivatives, e.g. phthalate or acetate succinate esters of hydroxypropyl methylcellulose
    • A61K9/5047—Cellulose ethers containing no ester groups, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants

Abstract

Настоящее изобретение относится к дозированной композиции пролонгированного на 24 часа высвобождения и к ее дозированной форме гидрохлорида венлафаксина и антидепрессанта, которая обеспечивает улучшенное регулирование уровней содержания лекарства в плазме крови по сравнению с традиционными композициями в виде таблеток, которые следует применять два или более раз в день, и дополнительно обеспечивает уменьшение случаев тошноты и рвоты по сравнению с традиционными таблетками. В соответствии с основным аспектом настоящее изобретение предусматривает улучшенное ядро сфероидов длительного высвобождения, состоящее из гидрохлорида венлафаксина и микрокристаллической целлюлозы, которое получают без добавления гидроксипропилметилцеллюлозы.Отчет о международном поиске был опубликован 1999.07.22.
EA200000487A 1997-11-05 1998-11-03 Композиция пролонгированного высвобождения EA200000487A1 (ru)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US96432897A 1997-11-05 1997-11-05
PCT/US1998/023338 WO1999022724A2 (en) 1997-11-05 1998-11-03 Extended release formulation containing venlafaxin

Publications (1)

Publication Number Publication Date
EA200000487A1 true EA200000487A1 (ru) 2000-10-30

Family

ID=25508423

Family Applications (1)

Application Number Title Priority Date Filing Date
EA200000487A EA200000487A1 (ru) 1997-11-05 1998-11-03 Композиция пролонгированного высвобождения

Country Status (39)

Country Link
EP (1) EP1028718B1 (ru)
JP (1) JP2001521892A (ru)
KR (1) KR20010031797A (ru)
CN (1) CN1278165A (ru)
AR (1) AR014012A1 (ru)
AT (1) ATE237320T1 (ru)
AU (1) AU747978B2 (ru)
BG (1) BG104397A (ru)
BR (1) BR9813179A (ru)
CA (1) CA2305242A1 (ru)
CL (1) CL2004001705A1 (ru)
CO (1) CO5011060A1 (ru)
CZ (1) CZ20001659A3 (ru)
DE (1) DE69813602T2 (ru)
DK (1) DK1028718T3 (ru)
EA (1) EA200000487A1 (ru)
EE (1) EE04577B1 (ru)
ES (1) ES2196620T3 (ru)
GE (1) GEP20043198B (ru)
HK (1) HK1029056A1 (ru)
HR (1) HRP20000213B1 (ru)
HU (1) HU225238B1 (ru)
ID (1) ID26317A (ru)
IL (1) IL135457A0 (ru)
MA (1) MA24691A1 (ru)
NO (1) NO20002126L (ru)
NZ (1) NZ504460A (ru)
PA (1) PA8462501A1 (ru)
PE (1) PE128699A1 (ru)
PL (1) PL341141A1 (ru)
PT (1) PT1028718E (ru)
SK (1) SK6472000A3 (ru)
SV (1) SV1998000131A (ru)
TR (1) TR200001232T2 (ru)
TW (1) TW555568B (ru)
UA (1) UA77145C2 (ru)
UY (2) UY25234A1 (ru)
WO (1) WO1999022724A2 (ru)
ZA (1) ZA9810081B (ru)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE60039132D1 (de) * 1999-04-06 2008-07-17 Sepracor Inc O-Desmethylvenlafaxin-Succinat
ATE367153T1 (de) * 1999-05-20 2007-08-15 Elan Corp Plc Multipartikuläre arzneizusammensetzungen mit gesteuerter wirkstoffabgabe enthaltend selektive inhibitoren der serotoninwiederaufnahme
IL146462A (en) 2001-11-13 2015-02-26 Lycored Bio Ltd Prolonged-release preparations containing as an active compound and analapaxin hydrochloride
BR0214742A (pt) * 2001-12-05 2004-09-14 Wyeth Corp Polimorfo cristalino de cloridrato de venlafaxina e métodos para sua preparação
WO2003050074A1 (en) * 2001-12-13 2003-06-19 Cadila Healthcare Limited Manufacture of venlafaxine hydrochloride and crystalline polymorphs thereof
AU2002217373A1 (en) * 2002-01-03 2003-07-15 Lek Pharmaceutical And Chemical Company D.D. Controlled release pharmaceutical formulation containing venlafaxine
AU2003226752A1 (en) * 2002-03-28 2003-10-13 Synthon B.V. Venlafaxine base
US6696496B2 (en) 2002-03-28 2004-02-24 Synthon Bv Low water-soluble venlafaxine salts
AU2003221535A1 (en) 2002-03-28 2003-10-13 Synthon B.V. Venlafaxine besylate
US20030190351A1 (en) * 2002-03-28 2003-10-09 Synthon Bv Extended release venlafaxine formulations
FR2845289B1 (fr) 2002-10-04 2004-12-03 Ethypharm Sa Spheroides, procede de preparation et compositions pharmaceutiques.
CA2415154C (en) * 2002-12-24 2009-06-16 Biovail Laboratories Inc. Modified release formulations of selective serotonin re-uptake inhibitors
DE10350194B4 (de) * 2003-10-28 2005-11-10 Bioplanta Arzneimittel Gmbh Verwendung von Extrakten aus Opuntien zur Behandlung von depressiven Verstimmungen und Erkrankungen
TW200503670A (en) * 2003-03-28 2005-02-01 Sandoz Ag Venlafaxine compositions
DE60307819T2 (de) * 2003-07-30 2007-10-04 Pharmathen S.A., Pallini Venlafaxine Hydrochloridformulierungen mit verzögerter Freisetzung
HUP0303382A2 (hu) * 2003-10-10 2005-08-29 EGIS Gyógyszergyár Rt. Venlafaxin-hidroklorid-tartalmú pelletek
SI1711169T1 (sl) 2004-02-04 2007-10-31 Alembic Ltd Obložene minitablete venlafaksin hidroklorida s podaljšanim sproščanjem
US7776358B2 (en) 2004-07-22 2010-08-17 Synthon Ip Inc. Extended release venlafaxine besylate tablets
WO2007112579A1 (en) * 2006-04-03 2007-10-11 Isa Odidi Drug delivery composition
WO2007129329A2 (en) * 2006-05-08 2007-11-15 Jubilant Organosys Limited Extended release pharmaceutical formulation comprising venlafaxine hydrochloride
CN102772390B (zh) * 2012-08-16 2014-01-08 乐普药业股份有限公司 一种盐酸文拉法辛缓释胶囊及其制备方法
FR3080278B1 (fr) * 2018-04-11 2021-04-30 Ghs Patents Ltd Procede de fabrication d'un spheroide de cannabidiol

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1561204A (en) * 1977-06-01 1980-02-13 Ici Ltd Sustained release pharmaceutical composition
US6440457B1 (en) * 1993-05-27 2002-08-27 Alza Corporation Method of administering antidepressant dosage form
PE57198A1 (es) * 1996-03-25 1998-10-10 American Home Prod Formula de liberacion prolongada
ZA97976B (en) * 1996-04-05 1997-08-18 Alza Corp Uniform drug delivery theraphy.

Also Published As

Publication number Publication date
TW555568B (en) 2003-10-01
AU1300399A (en) 1999-05-24
EP1028718A2 (en) 2000-08-23
AU747978B2 (en) 2002-05-30
KR20010031797A (ko) 2001-04-16
HRP20000213B1 (en) 2004-04-30
EE200000212A (et) 2001-04-16
WO1999022724A2 (en) 1999-05-14
HU225238B1 (en) 2006-08-28
TR200001232T2 (tr) 2000-12-21
PE128699A1 (es) 2000-01-06
NZ504460A (en) 2003-01-31
PA8462501A1 (es) 2000-05-24
BG104397A (en) 2001-02-28
UA77145C2 (en) 2006-11-15
EP1028718B1 (en) 2003-04-16
UY25234A1 (es) 2000-12-29
AR014012A1 (es) 2001-01-31
HUP0004287A2 (hu) 2002-04-29
ID26317A (id) 2000-12-14
GEP20043198B (en) 2004-03-25
DE69813602D1 (de) 2003-05-22
WO1999022724A3 (en) 1999-07-22
PT1028718E (pt) 2003-07-31
HK1029056A1 (en) 2001-03-23
CO5011060A1 (es) 2001-02-28
NO20002126L (no) 2000-05-04
ATE237320T1 (de) 2003-05-15
ZA9810081B (en) 2000-05-04
CN1278165A (zh) 2000-12-27
HRP20000213A2 (en) 2000-12-31
CL2004001705A1 (es) 2005-06-03
CZ20001659A3 (cs) 2001-10-17
EE04577B1 (et) 2006-02-15
SV1998000131A (es) 1999-11-18
NO20002126D0 (no) 2000-04-26
DK1028718T3 (da) 2003-07-28
HUP0004287A3 (en) 2002-05-28
IL135457A0 (en) 2001-05-20
MA24691A1 (fr) 1999-07-01
DE69813602T2 (de) 2003-11-06
ES2196620T3 (es) 2003-12-16
BR9813179A (pt) 2000-08-22
SK6472000A3 (en) 2000-11-07
UY25692A1 (es) 2000-03-31
PL341141A1 (en) 2001-03-26
CA2305242A1 (en) 1999-05-14
JP2001521892A (ja) 2001-11-13

Similar Documents

Publication Publication Date Title
EA200000487A1 (ru) Композиция пролонгированного высвобождения
UY24613A1 (es) Formula de liberacion controlada que comprende venlafaxina
RU2008143545A (ru) Применение антагониста рецептора ат-1 или модулятора рецептора ат-2 для лечения болезней, связанных с увеличением содержания рецепторов ат-1 или ат-2
MY129234A (en) Oral pharmaceutical forms of administration with a delayed action with tramadol.
MXPA04003132A (es) Formas orales de administracion de propiverina o sus sales farmaceuticas aceptables con liberacion prolongada.
RU2008111710A (ru) Композиция для чрескожной доставки лекарственного средства
MX9403386A (es) Pirrolidin-3-il-alquilpiperidinas sustituidas.
EA199900026A1 (ru) Быстрорастворимая таблетка гидробромида галантамина
DK0840603T3 (da) Farmaceutisk præparat af L-dopa-ethylester
BR0111868A (pt) Composições farmacêuticas
ES2191987T3 (es) Formas de dosificacion de ribavirina solidas, administrables oralmente, y procedimiento de fabricacion.
DE60235648D1 (de) Pharmazeutische metformintablette mit verlängerter freisetzung
UY24308A1 (es) Tabletas exentas de aglutinante que contienen tramadol o una sal de tramadol, para administracion oral
NO20013060D0 (no) Kontrollert frigjörende farmasöytisk preparat med tilidinmesylat som virkestoff
FR2729857B1 (fr) Compositions pharmaceutiques sous forme de comprimes a liberation prolongee a base de granules en polysaccharides de haut poids moleculaire
NO996049D0 (no) Kontrollert-frigjøring farmasoeytisk preparat med ACE inhibitor som aktivt middel
SE8901003D0 (sv) Snabbloesliga preparat
EA200100947A1 (ru) Жевательные таблетки с высоким содержанием n-ацетилцистеина
UA41978C2 (ru) N-метил-n-[(1s)-1-фенил-2-((3s)-3-гидроксипирролидин-1-ил)этил]-2,2- дифенилацетамид гидрохлорид, способ его получения и фармацевтическая композиция
NO20013891L (no) Sammensetninger omfattende citalopram
FI955837A0 (fi) Menetelmä suun kautta annettavan, kiinteän, diklofenaakkia sisältävän annostelumuodon valmistamiseksi
TR200200978T2 (tr) Yeni mirtazapin formülasyonu
WO2002064093A3 (en) Stabilized pharmaceutical and thyroid hormone compositions and method of preparation
WO2003105811A3 (en) PROGRESSIVE RELEASE COMPOSITIONS AND METHOD OF USE
PT1265614E (pt) Nova forma galenica para administracao oral de libertacao prolongada de molsidomina